WallStSmart

Insmed Inc (INSM)vsVyne Therapeutics Inc (VYNE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 106290% more annual revenue ($606.42M vs $570,000). VYNE leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

VYNE

Avoid

34

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

VYNE2 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
54.8%10/10

Revenue surging 54.8% year-over-year

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

VYNE4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.15M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-67.0%2/10

ROE of -67.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : VYNE

The strongest argument for VYNE centers on Price/Book, Revenue Growth. Revenue growth of 54.8% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : VYNE

The primary concerns for VYNE are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while VYNE is a hypergrowth play — different risk/reward profiles.

VYNE carries more volatility with a beta of 2.03 — expect wider price swings.

VYNE is growing revenue faster at 54.8% — sustainability is the question.

VYNE generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Vyne Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.

Visit Website →

Want to dig deeper into these stocks?